178 related articles for article (PubMed ID: 37326164)
1. COVID-19 infection in myasthenia gravis: Clinical course and outcomes.
Thomas EV; Bou G; Barton S; Hutto S; Garcia-Santibanez R
Muscle Nerve; 2023 Aug; 68(2):171-175. PubMed ID: 37326164
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 pandemic year in a sample of Polish myasthenia gravis patients: an observational study.
Rzepiński Ł; Zawadka-Kunikowska M
Neurol Neurochir Pol; 2022; 56(1):61-67. PubMed ID: 34346049
[TBL] [Abstract][Full Text] [Related]
3. Case series of COVID-19 in patients with myasthenia gravis: a single institution experience.
Županić S; Perić Šitum M; Majdak M; Karakaš M; Bašić S; Sporiš D
Acta Neurol Belg; 2021 Aug; 121(4):1039-1044. PubMed ID: 33797054
[TBL] [Abstract][Full Text] [Related]
4. Clinical features and outcomes of patients with myasthenia gravis affected by COVID-19: A single-center study.
Karimi N; Fatehi F; Okhovat AA; Abdi S; Sinaei F; Sikaroodi H; Vahabi Z; Nafissi S
Clin Neurol Neurosurg; 2022 Nov; 222():107441. PubMed ID: 36174408
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 in patients with myasthenia gravis.
Anand P; Slama MCC; Kaku M; Ong C; Cervantes-Arslanian AM; Zhou L; David WS; Guidon AC
Muscle Nerve; 2020 Aug; 62(2):254-258. PubMed ID: 32392389
[TBL] [Abstract][Full Text] [Related]
6. Intravenous immunoglobulin for myasthenia gravis.
Gajdos P; Chevret S; Toyka KV
Cochrane Database Syst Rev; 2012 Dec; 12(12):CD002277. PubMed ID: 23235588
[TBL] [Abstract][Full Text] [Related]
7. Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis.
Stascheit F; Grittner U; Hoffmann S; Mergenthaler P; Schroeter M; Ruck T; Pawlitzki M; Blaes F; Kaiser J; Schara U; Della-Marina A; Thieme A; Hagenacker T; Jacobi C; Berger B; Urban PP; Knop KC; Schalke B; Lee DH; Kalischewski P; Wiendl H; Meisel A
J Neurol; 2023 Jan; 270(1):1-12. PubMed ID: 36166068
[TBL] [Abstract][Full Text] [Related]
8. Impact of COVID-19 Infection and Its Association With Previous Vaccination in Patients With Myasthenia Gravis in Korea: A Multicenter Retrospective Study.
Han HJ; Kim SW; Kim H; So J; Lee EJ; Lim YM; Lee JH; Lee MA; Kim BJ; Baek SH; Lee HS; Sohn E; Kim S; Park JS; Kang M; Park HJ; Yoon BA; Kim JK; Seok HY; Kim S; Min JH; Chung YH; Cho JH; Kim JE; Oh SI; Shin HY
J Korean Med Sci; 2024 May; 39(18):e150. PubMed ID: 38742290
[TBL] [Abstract][Full Text] [Related]
9. Intravenous immunoglobulin for myasthenia gravis.
Gajdos P; Chevret S; Toyka K
Cochrane Database Syst Rev; 2008 Jan; (1):CD002277. PubMed ID: 18254004
[TBL] [Abstract][Full Text] [Related]
10. Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients.
Nelke C; Stascheit F; Eckert C; Pawlitzki M; Schroeter CB; Huntemann N; Mergenthaler P; Arat E; Öztürk M; Foell D; Schreiber S; Vielhaber S; Gassa A; Stetefeld H; Schroeter M; Berger B; Totzeck A; Hagenacker T; Meuth SG; Meisel A; Wiendl H; Ruck T
J Neuroinflammation; 2022 Apr; 19(1):89. PubMed ID: 35413850
[TBL] [Abstract][Full Text] [Related]
11. Clinical course and outcome of an outpatient clinic population with myasthenia gravis and COVID-19.
Gungor Tuncer O; Deymeer F
Muscle Nerve; 2022 Apr; 65(4):447-452. PubMed ID: 35040147
[TBL] [Abstract][Full Text] [Related]
12. Myasthenia gravis and COVID-19: A case series and comparison with literature.
Saied Z; Rachdi A; Thamlaoui S; Nabli F; Jeridi C; Baffoun N; Kaddour C; Belal S; Ben Sassi S
Acta Neurol Scand; 2021 Sep; 144(3):334-340. PubMed ID: 33914898
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 and generalized Myasthenia Gravis exacerbation: A case report.
Singh S; Govindarajan R
Clin Neurol Neurosurg; 2020 Sep; 196():106045. PubMed ID: 32634699
[TBL] [Abstract][Full Text] [Related]
14. The impact of SARS-CoV-2 immunization on COVID-19 disease course in people with myasthenia gravis.
Bakirtzis C; Boziki MK; Karakasi MV; Moysiadis T; Grigoriadis N
Muscle Nerve; 2023 May; 67(5):412-416. PubMed ID: 36814101
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival.
Jakubíková M; Týblová M; Tesař A; Horáková M; Vlažná D; Ryšánková I; Nováková I; Dolečková K; Dušek P; Piťha J; Voháňka S; Bednařík J
Eur J Neurol; 2021 Oct; 28(10):3418-3425. PubMed ID: 34080271
[TBL] [Abstract][Full Text] [Related]
16. Myasthenia gravis exacerbation and myasthenic crisis associated with COVID-19: case series and literature review.
Rodrigues CL; de Freitas HC; Lima PRO; de Oliveira Junior PH; Fernandes JMA; D'Almeida JAC; Nóbrega PR
Neurol Sci; 2022 Apr; 43(4):2271-2276. PubMed ID: 35039987
[TBL] [Abstract][Full Text] [Related]
17. Intravenous immunoglobulin for myasthenia gravis.
Gajdos P; Chevret S; Toyka K
Cochrane Database Syst Rev; 2003; (2):CD002277. PubMed ID: 12804431
[TBL] [Abstract][Full Text] [Related]
18. Impact of Coronavirus Disease 2019 in a French Cohort of Myasthenia Gravis.
Solé G; Mathis S; Friedman D; Salort-Campana E; Tard C; Bouhour F; Magot A; Annane D; Clair B; Le Masson G; Soulages A; Duval F; Carla L; Violleau MH; Saulnier T; Segovia-Kueny S; Kern L; Antoine JC; Beaudonnet G; Audic F; Kremer L; Chanson JB; Nadaj-Pakleza A; Stojkovic T; Cintas P; Spinazzi M; Foubert-Samier A; Attarian S
Neurology; 2021 Apr; 96(16):e2109-e2120. PubMed ID: 33568541
[TBL] [Abstract][Full Text] [Related]
19. Maintenance IVIg therapy in myasthenia gravis does not affect disease activity.
Hellmann MA; Mosberg-Galili R; Lotan I; Steiner I
J Neurol Sci; 2014 Mar; 338(1-2):39-42. PubMed ID: 24267740
[TBL] [Abstract][Full Text] [Related]
20. Intravenous immunoglobulin for myasthenia gravis.
Gajdos P; Chevret S; Toyka K
Cochrane Database Syst Rev; 2006 Apr; (2):CD002277. PubMed ID: 16625559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
